Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

International Society of Geriatric Oncology

The International Society of Geriatric Oncology, or Society International d'Oncologie Geriatrique in French, thus the acronym SIOG, was established in 2000 and was authoritatively enrolled as a Not-revenue driven association under the Swiss law in October 2012. SIOG is a multidisciplinary society, incorporating doctors in the fields of oncology and geriatrics, and associated wellbeing experts and has more than 1130 individuals in more than 75 nations around the globe. The significant danger element for disease is age, and with the maturing of the total populace, a noteworthy epidemiologic test is before us. The objective of SIOG is to encourage the advancement of wellbeing experts in the field of geriatric oncology, keeping in mind the end goal to improve treatment of more established grown-ups with tumour. Disperse information with a specific end goal to keep up a high basic standard of social insurance in more established growth patients. Incorporate geriatric oncology in the educational program for medicinal and nursing instruction to guarantee an elevated requirement of capability for human services experts. Address the deficiency of pro oncologists/geriatricians and unified wellbeing staff in geriatric oncology. Increment open attention to the overall malignancy in the elderly pestilence. Incorporate geriatric assessment (counting comorbidities) into oncology basic leadership and rules enhance the nature of counteractive action, finding, treatment, and line-up of more established patients with malignancies. Address issues of access to mind, including the necessities of the guardian. Create interdisciplinary geriatric oncology facilities. Create, test and disperse simple screening apparatuses make a reasonable and operational meaning of weakness/fragility material to oncology. Increment the pertinence of clinical trials for more seasoned patients. Enhance research in the field of geriatric oncology Promote multidisciplinary, essential/translational exploration on the interface of maturing and tumour.

Read More»